Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005

A report from the children's oncology group

Stephen P. Hunger, Xiaomin Lu, Meenakshi Devidas, Bruce M. Camitta, Paul S. Gaynon, Naomi J. Winick, Gregory H. Reaman, William L. Carroll

Research output: Contribution to journalArticle

489 Citations (Scopus)

Abstract

Purpose: To examine population-based improvements in survival and the impact of clinical covariates on outcome among children and adolescents with acute lymphoblastic leukemia (ALL) enrolled onto Children's Oncology Group (COG) clinical trials between 1990 and 2005. Patients and Methods: In total, 21,626 persons age 0 to 22 years were enrolled onto COG ALL clinical trials from 1990 to 2005, representing 55.8% of ALL cases estimated to occur among US persons younger than age 20 years during this period. This period was divided into three eras (1990-1994, 1995-1999, and 2000-2005) that included similar patient numbers to examine changes in 5- and 10-year survival over time and the relationship of those changes in survival to clinical covariates, with additional analyses of cause of death. Results: Five-year survival rates increased from 83.7% in 1990-1994 to 90.4% in 2000-2005 (P < .001). Survival improved significantly in all subgroups (except for infants age ≤ 1 year), including males and females; those age 1 to 9 years, 10+ years, or 15+ years; in whites, blacks, and other races; in Hispanics, non-Hispanics, and patients of unknown ethnicity; in those with B-cell or T-cell immunophenotype; and in those with National Cancer Institute (NCI) standard- or high-risk clinical features. Survival rates for infants changed little, but death following relapse/disease progression decreased and death related to toxicity increased. Conclusion: This study documents ongoing survival improvements for children and adolescents with ALL. Thirty-six percent of deaths occurred among children with NCI standard-risk features emphasizing that efforts to further improve survival must be directed at both high-risk subsets and at those children predicted to have an excellent chance for cure.

Original languageEnglish (US)
Pages (from-to)1663-1669
Number of pages7
JournalJournal of Clinical Oncology
Volume30
Issue number14
DOIs
StatePublished - May 10 2012

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Survival
National Cancer Institute (U.S.)
Survival Rate
Clinical Trials
Hispanic Americans
Disease Progression
Cause of Death
B-Lymphocytes
T-Lymphocytes
Recurrence
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005 : A report from the children's oncology group. / Hunger, Stephen P.; Lu, Xiaomin; Devidas, Meenakshi; Camitta, Bruce M.; Gaynon, Paul S.; Winick, Naomi J.; Reaman, Gregory H.; Carroll, William L.

In: Journal of Clinical Oncology, Vol. 30, No. 14, 10.05.2012, p. 1663-1669.

Research output: Contribution to journalArticle

Hunger, Stephen P. ; Lu, Xiaomin ; Devidas, Meenakshi ; Camitta, Bruce M. ; Gaynon, Paul S. ; Winick, Naomi J. ; Reaman, Gregory H. ; Carroll, William L. / Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005 : A report from the children's oncology group. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 14. pp. 1663-1669.
@article{699ce901f7324db7aaef813e16e5b359,
title = "Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children's oncology group",
abstract = "Purpose: To examine population-based improvements in survival and the impact of clinical covariates on outcome among children and adolescents with acute lymphoblastic leukemia (ALL) enrolled onto Children's Oncology Group (COG) clinical trials between 1990 and 2005. Patients and Methods: In total, 21,626 persons age 0 to 22 years were enrolled onto COG ALL clinical trials from 1990 to 2005, representing 55.8{\%} of ALL cases estimated to occur among US persons younger than age 20 years during this period. This period was divided into three eras (1990-1994, 1995-1999, and 2000-2005) that included similar patient numbers to examine changes in 5- and 10-year survival over time and the relationship of those changes in survival to clinical covariates, with additional analyses of cause of death. Results: Five-year survival rates increased from 83.7{\%} in 1990-1994 to 90.4{\%} in 2000-2005 (P < .001). Survival improved significantly in all subgroups (except for infants age ≤ 1 year), including males and females; those age 1 to 9 years, 10+ years, or 15+ years; in whites, blacks, and other races; in Hispanics, non-Hispanics, and patients of unknown ethnicity; in those with B-cell or T-cell immunophenotype; and in those with National Cancer Institute (NCI) standard- or high-risk clinical features. Survival rates for infants changed little, but death following relapse/disease progression decreased and death related to toxicity increased. Conclusion: This study documents ongoing survival improvements for children and adolescents with ALL. Thirty-six percent of deaths occurred among children with NCI standard-risk features emphasizing that efforts to further improve survival must be directed at both high-risk subsets and at those children predicted to have an excellent chance for cure.",
author = "Hunger, {Stephen P.} and Xiaomin Lu and Meenakshi Devidas and Camitta, {Bruce M.} and Gaynon, {Paul S.} and Winick, {Naomi J.} and Reaman, {Gregory H.} and Carroll, {William L.}",
year = "2012",
month = "5",
day = "10",
doi = "10.1200/JCO.2011.37.8018",
language = "English (US)",
volume = "30",
pages = "1663--1669",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "14",

}

TY - JOUR

T1 - Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005

T2 - A report from the children's oncology group

AU - Hunger, Stephen P.

AU - Lu, Xiaomin

AU - Devidas, Meenakshi

AU - Camitta, Bruce M.

AU - Gaynon, Paul S.

AU - Winick, Naomi J.

AU - Reaman, Gregory H.

AU - Carroll, William L.

PY - 2012/5/10

Y1 - 2012/5/10

N2 - Purpose: To examine population-based improvements in survival and the impact of clinical covariates on outcome among children and adolescents with acute lymphoblastic leukemia (ALL) enrolled onto Children's Oncology Group (COG) clinical trials between 1990 and 2005. Patients and Methods: In total, 21,626 persons age 0 to 22 years were enrolled onto COG ALL clinical trials from 1990 to 2005, representing 55.8% of ALL cases estimated to occur among US persons younger than age 20 years during this period. This period was divided into three eras (1990-1994, 1995-1999, and 2000-2005) that included similar patient numbers to examine changes in 5- and 10-year survival over time and the relationship of those changes in survival to clinical covariates, with additional analyses of cause of death. Results: Five-year survival rates increased from 83.7% in 1990-1994 to 90.4% in 2000-2005 (P < .001). Survival improved significantly in all subgroups (except for infants age ≤ 1 year), including males and females; those age 1 to 9 years, 10+ years, or 15+ years; in whites, blacks, and other races; in Hispanics, non-Hispanics, and patients of unknown ethnicity; in those with B-cell or T-cell immunophenotype; and in those with National Cancer Institute (NCI) standard- or high-risk clinical features. Survival rates for infants changed little, but death following relapse/disease progression decreased and death related to toxicity increased. Conclusion: This study documents ongoing survival improvements for children and adolescents with ALL. Thirty-six percent of deaths occurred among children with NCI standard-risk features emphasizing that efforts to further improve survival must be directed at both high-risk subsets and at those children predicted to have an excellent chance for cure.

AB - Purpose: To examine population-based improvements in survival and the impact of clinical covariates on outcome among children and adolescents with acute lymphoblastic leukemia (ALL) enrolled onto Children's Oncology Group (COG) clinical trials between 1990 and 2005. Patients and Methods: In total, 21,626 persons age 0 to 22 years were enrolled onto COG ALL clinical trials from 1990 to 2005, representing 55.8% of ALL cases estimated to occur among US persons younger than age 20 years during this period. This period was divided into three eras (1990-1994, 1995-1999, and 2000-2005) that included similar patient numbers to examine changes in 5- and 10-year survival over time and the relationship of those changes in survival to clinical covariates, with additional analyses of cause of death. Results: Five-year survival rates increased from 83.7% in 1990-1994 to 90.4% in 2000-2005 (P < .001). Survival improved significantly in all subgroups (except for infants age ≤ 1 year), including males and females; those age 1 to 9 years, 10+ years, or 15+ years; in whites, blacks, and other races; in Hispanics, non-Hispanics, and patients of unknown ethnicity; in those with B-cell or T-cell immunophenotype; and in those with National Cancer Institute (NCI) standard- or high-risk clinical features. Survival rates for infants changed little, but death following relapse/disease progression decreased and death related to toxicity increased. Conclusion: This study documents ongoing survival improvements for children and adolescents with ALL. Thirty-six percent of deaths occurred among children with NCI standard-risk features emphasizing that efforts to further improve survival must be directed at both high-risk subsets and at those children predicted to have an excellent chance for cure.

UR - http://www.scopus.com/inward/record.url?scp=84863772728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863772728&partnerID=8YFLogxK

U2 - 10.1200/JCO.2011.37.8018

DO - 10.1200/JCO.2011.37.8018

M3 - Article

VL - 30

SP - 1663

EP - 1669

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 14

ER -